Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) announced the publication of a scientific manuscript in the Journal of Cystic Fibrosis, detailing the results of ELX-02 in restoring CFTR function in human-derived intestinal organoids. The findings indicate that ELX-02 increased CFTR activity in a dose-dependent manner, showing a 5-fold increase in CFTR mRNA compared to vehicle treatment. The study supports the ongoing Phase 2 clinical trial for patients with G542X nonsense alleles, who currently have limited treatment options. Top-line data is expected in the first half of 2021.
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) announced the publication of a scientific manuscript detailing the results of a Phase 1B trial for its drug candidate ELX-02, aimed at treating cystic fibrosis. Published in the Journal of Clinical Pharmacology in Drug Development, the study found no serious adverse events, supporting the drug's favorable safety profile. Dr. Goddeeris expressed optimism regarding ongoing Phase 2 trials and anticipates top-line data in the first half of 2021. Eloxx focuses on RNA-modulating therapies for diseases caused by nonsense mutations.
Eloxx Pharmaceuticals announced the publication of a scientific manuscript detailing the results of its Phase 1 renal impairment trial for ELX-02 in patients with nephropathic cystinosis. The study found that ELX-02 was well tolerated and demonstrated a consistent pharmacokinetic profile across varying degrees of renal insufficiency. This research enables targeted individualized dosing of ELX-02, supporting ongoing Phase 2 programs in both cystic fibrosis and autosomal dominant polycystic kidney disease. The findings were published in the Journal of Clinical Pharmacology.
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced an expansion of its agreement with the Cystic Fibrosis Foundation, now including global funding for its Phase 2 clinical trial program for ELX-02, targeting cystic fibrosis. The trials, sanctioned by relevant health networks in Europe and the U.S., aim to address significant unmet medical needs. The company anticipates reporting top-line data in the first half of 2021, contingent on COVID-19 disruptions. ELX-02 has received orphan drug designations from the FDA and EMA, indicating its potential in treating rare diseases.
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced that CEO Dr. Gregory Williams will participate in the Piper Sandler 32nd Annual Virtual Growth Conference. The fireside chat will be accessible to registered attendees from November 23 at 10:00 AM ET to December 3, 2020. One-on-one investor meetings are scheduled for December 1, 2020, through Piper Sandler. Eloxx is developing novel therapeutics for cystic fibrosis and other diseases caused by nonsense mutations, with their lead product candidate, ELX-02, currently in early clinical development.
Eloxx Pharmaceuticals reported its financial results for Q3 2020, revealing a net loss of $6.6 million, down from $12.9 million year-over-year. Cash reserves stand at $30.6 million, sufficient through 2021. The independent Safety Review Committees have approved dose escalation in Phase 2 cystic fibrosis trials, with top-line data expected in H1 2021, contingent on pandemic-related disruptions. Preclinical studies in ADPKD and inherited retinal disorders are progressing. Eloxx's lead compound, ELX-02, is focused on treating cystic fibrosis and is presently in clinical trials.
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced the publication of two scientific manuscripts in leading journals. The first manuscript reviews ELX-02's development for treating nonsense-mediated genetic diseases, authored by Professor Eitan Kerem, supporting ongoing Phase 2 trials. The second highlights the functional activity of small molecule compounds in a mouse model, showcasing their potential in treating inherited retinal disorders and systemic diseases like cystic fibrosis. Eloxx is advancing IND-enabling preclinical studies for its ERSG compounds targeting various genetic disorders.
Eloxx Pharmaceuticals (NASDAQ: ELOX) has presented significant data from two abstracts at the North American Cystic Fibrosis Virtual Conference. The research focuses on ELX-02, a drug aimed at treating cystic fibrosis through the read-through of premature stop codons. Notably, results indicate ELX-02's selective action without affecting native stop codons. The company is advancing Phase 2 clinical trials across Europe, Israel, and the U.S., eager to report top-line data from these trials soon.
Eloxx Pharmaceuticals (NASDAQ: ELOX) plans to release its Q3 2020 financial and operational results on November 5, 2020. A conference call and webcast will be held at 4:30 p.m. ET to provide updates. The company specializes in developing innovative therapeutics targeting cystic fibrosis and other diseases caused by nonsense mutations. Its lead candidate, ELX-02, is designed to restore production of functional proteins. Eloxx also has preclinical programs addressing kidney and ocular genetic disorders.
Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company, announced the appointment of Professor Eitan Kerem as Senior Consultant. Dr. Kerem will advise on the company's cystic fibrosis program, focusing on strategic leadership and medical safety review. Eloxx is advancing its Phase 2 clinical trial for ELX-02, aimed at treating cystic fibrosis caused by nonsense mutations. Dr. Kerem's experience will be crucial as Eloxx approaches significant milestones in the trial. The company emphasizes the urgent need for therapies in this area as they prepare to report top-line results.